Bristol-Myers Squibb
2 activist/short documents on this target.
Timeline
2019-03-01
Starboard Value · full deck
BMY's $91B Celgene deal bets the company on a REVLIMID patent cliff and pipeline requiring 10 blockbusters in 8 years — shareholders should vote no and pursue a standalone Amgen-style transformation.
N5 V3
2019-03-18
Starboard Value · full deck
BMY is overpaying ~$30B for Celgene's risky pipeline, betting on 10 blockbusters in 8 years vs 3 in 15; shareholders should vote against and unlock 900bps of standalone margin upside.
N5 V3